Company: HURA
Filing Date: 2025-11-04
Form Type: 8-K
Source: 0001193125-25-263523
Chunk: 0

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-04
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive Agreement.

On November 3, 2025, TuHURA Biosciences, Inc. (the “ Company”) entered into an At The Market Offering Agreement (the “ Offering Agreement”) with H. C. Wainwright & Co., LLC (“ Wainwright”) with respect to an at the market offering program under which the Company may offer and sell shares of its common stock, $0.001 par value (“ Common Stock”), having an aggregate offering price of up to $50,000,000 through Wainwright as its sales agent. The shares of Common Stock to be offered and sold under the Offering Agreement will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-291239), which was filed with the Securities and Exchange Commission (“ SEC”) on November 3, 2025 (the “ Registration Statement”). A prospectus supplement related to this at the market offering program with Wainwright was filed as part of the Registration Statement on November 3, 2023. No shares of Common Stock may be sold pursuant to the Offering Agreement until the Registration Statement has been declared effective by the SEC. Sales of the shares of Common Stock, if any, will be made in “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended (the “ Securities Act”). Wainwright will use commercially reasonable efforts to sell the shares of Common Stock.

The Company will pay Wainwright a cash commission of 3.0% of the gross sales price of the shares of Common Stock that Wainwright sells pursuant to the Offering Agreement. In addition, the Company has agreed to reimburse Wainwright for the documented fees and costs of its legal counsel reasonably incurred in connection with entering into the transactions contemplated by the Offering Agreement in an amount not to exceed $75,000 in the aggregate.

The Company is not obligated to sell any of the shares of Common Stock under the Offering Agreement and no assurance can be given that the Company will sell any shares of Common Stock under the Offering Agreement, or if such sales occur, no assurance can be given as to the price or number of shares of Common Stock that will be sold, or the dates on which any such sales will take place. The Company or Wainwright may at any time suspend offers and sales under the Offering Agreement and the Offering Agreement may be terminated by either the Company or Wainwright upon proper